GSK Respiratory OTC Sales Up 13% In Q1
This article was originally published in The Tan Sheet
Executive Summary
Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan